NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The approval marks a significant step forward in the fight against Ebola, particularly in regions where intravenous treatments are challenging to administer.
NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses, and according to the company, it is the only orally administered Ebola treatment candidate currently under consideration for clinical testing. The oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale. This is critical for the Democratic Republic of Congo, which has faced recurring Ebola outbreaks and where healthcare infrastructure often struggles to support complex medical procedures.
NanoViricides noted that the next steps include obtaining approvals from the DRC National Ethics Committee and the regulatory agency ACOREP before initiating the study. The company also stated that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. This existing regulatory clearance for mpox could facilitate the approval process for the Ebola indication.
The potential impact of an effective oral Ebola treatment is substantial. Current standard-of-care therapies require intravenous administration, which necessitates trained medical personnel, sterile equipment, and cold chain logistics—all of which are often scarce in outbreak zones. An oral gummy formulation could be distributed more easily, allowing for earlier treatment and potentially reducing transmission. If successful, NV-387 could become a critical tool in global health security, particularly for future Ebola outbreaks in Africa.
NanoViricides is a clinical stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral for multiple viral infections, including RSV, COVID-19, influenza, and mpox. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several viral diseases, including Ebola and Marburg viruses. However, the company cautions that drug development is extremely lengthy and requires substantial capital, and there can be no assurance that NV-387 will show sufficient effectiveness and safety in human clinical trials.
The approval of the Phase II trial proposal is a promising development for NanoViricides and for global health efforts to combat Ebola. The company’s innovative approach using oral gummies could revolutionize treatment in outbreak settings, making therapy more accessible and scalable. Investors and public health officials will be closely watching the progress of this trial, as it could pave the way for a new class of antiviral treatments.
For more information, visit the company’s newsroom at https://nnw.fm/NNVC.
